Companies /Healthcare

Nektar Therapeutics

NASDAQ: NKTR Biotechnology
$30.20
▼ $2.34 (−7.19%) today
Markets closed · 4:43am ET

24/7 Wall St. View

NKTR at a Glance

Valuation
Market cap
$1.1B
Profitability
Revenue (TTM)
$52.2M
EPS (TTM)
$-22.47
Price
52-week range
$30 – $109
Street target
$131.92
Earnings
Q3 2026 EPS
$-1.63
vs. $-2.07 est.
+21.2%

Headquartered in San Francisco, CA Fiscal year ends December NASDAQ: NKTR nektar.com

About Nektar Therapeutics

Nektar Therapeutics is a clinical-stage biotechnology company developing treatments that target the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. Its lead candidate, rezpegaldesleukin (REZPEG, NKTR-358), is a first-in-class regulatory T cell (Treg) stimulator now in Phase 3 development. Three global ZENITH AD registrational trials are underway in moderate-to-severe atopic dermatitis, and the ZENITH AA registrational trial in alopecia areata is set to start in December 2026. REZPEG is also being evaluated in Type 1 diabetes mellitus. The preclinical pipeline includes the bivalent TNFR2 antibody and bispecific programs NKTR-0165 and NKTR-0166 and a modified hematopoietic colony stimulating factor protein, NKTR-422. Current revenue is non-cash royalty revenue related to previously sold future royalty streams. The company also holds an equity-method investment in Gannet BioChem. It funds R&D from a cash and investment balance of about $952.9 million, built up through equity raises in 2026. Updated

NKTR Coverage

Frequently Asked Questions

What does Nektar Therapeutics do?

Nektar Therapeutics is a clinical-stage biotechnology company developing treatments that target the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases.

What is the NKTR stock price target?

The Wall Street consensus 12-month price target for NKTR is $131.92.